🏛️ Verified NIH Record • Updated 2026-05-12
DFMO Maintenance for Patients With Relapsed/Refractory Ewing Sarcoma or Osteosarcoma (NCT06892678)
🟢 Recruiting Phase1 / Phase2 💊 Investigational Drug / Biologic Sponsor: Montefiore Medical Center
🩺 Plain-English Summary (8th-Grade Level)
The purpose of this study is to determine the feasibility of administering DL-alpha-difluoromethylornithine (DFMO) to patients with relapsed Ewing sarcoma and osteosarcoma who have completed all planned therapy and have no evidence of disease.
Who can join: Review the eligibility criteria below.
Location: Montefiore Medical Center — The Bronx, New York
Age range: Not specified to 39 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (1 Sites)
- Montefiore Medical Center — The Bronx, New York
📞 Contact the Study Coordinator
Phone: (718) 741-2356
Email: rzylber@montefiore.org
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Osteosarcoma Recurrent
Explore by condition: All Osteosarcoma Recurrent clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.